Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotechnology company engaged in the discovery, development, and commercialization of therapeutic medicines for serious medical conditions. Its portfolio includes approved products such as Eylea, a vascular endothelial growth factor inhibitor used in ophthalmology, and Dupixent, a monoclonal antibody targeting the interleukin‑4 receptor alpha subunit used in immunology and respiratory indications. The company also maintains a robust pipeline of investigational agents across oncology, infectious diseases, and rare genetic disorders. Regeneron serves patients worldwide through its commercial operations and collaborations with other pharmaceutical firms.

Headquartered in Tarrytown, New York, the company operates research and development facilities in the United States and Europe, and it maintains manufacturing sites that support both clinical supply and commercial production. As a publicly traded entity listed on the NASDAQ under the ticker REGN, Regeneron accesses capital markets to fund its research programs. Its global footprint includes offices and distribution networks that enable it to market its therapies in North America, Europe, Asia, and other regions. While specific employee counts are not disclosed here, the organization employs a substantial workforce dedicated to science, manufacturing, and commercial functions.

Regeneron distinguishes itself through proprietary antibody discovery technologies, notably the VelocImmune and VelociSuite platforms, which enable the rapid generation of fully human monoclonal antibodies. This technological edge has contributed to the company's reputation for delivering first‑in‑class and best‑in‑class therapies, such as the VEGF trap Eylea and the IL‑4Rα antagonist Dupixent. The firm places a strong emphasis on internal research, maintaining a high proportion of its pipeline originating from in‑house discovery efforts. Regeneron’s scientific approach is frequently recognized through publications, patents, and awards that highlight its contributions to biomedical innovation.

Although Regeneron operates as an independent publicly traded corporation, it engages in strategic partnerships to expand the reach of its products; for example, it co‑develops and co‑promotes Dupixent with Sanofi and collaborates with Bayer on the commercialization of Eylea outside the United States. The company also holds wholly owned subsidiaries that handle specific functions such as manufacturing, diagnostics, and international commercial activities. These alliances and subsidiary structures allow Regeneron to leverage external expertise while retaining control over its core research agenda and intellectual property.